Related Experiment Video
Updated: May 13, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Belimumab: targeted therapy for lupus
Preeta K Chugh1, Bhupinder S Kalra
1Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India. docpreeta@yahoo.com
International Journal of Rheumatic Diseases
|February 28, 2013
Summary
Belimumab, a new biologic therapy for systemic lupus erythematosus (SLE), effectively treats active disease in patients with autoantibodies. Clinical trials show it is well-tolerated and offers a promising alternative to traditional treatments.
Area of Science:
- Immunology and Rheumatology
- Pharmacology and Therapeutics
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystemic effects, characterized by unpredictable flares and remissions.
- Current SLE management relies on corticosteroids, antimalarials, and immunosuppressants, often associated with significant side effects.
- Belimumab, a B-lymphocyte stimulator (BLyS) inhibitor, represents a novel targeted therapy for SLE.
Purpose of the Study:
- To review the role of belimumab in treating systemic lupus erythematosus (SLE).
- To discuss the clinical trials that led to the FDA approval of belimumab for SLE.
- To evaluate belimumab's efficacy and safety in active SLE patients.
Main Methods:
- Review of randomized, double-blind, phase III clinical trials (BLISS-52 and BLISS-76).
- Assessment of patient response using the SLE Responder Index (SRI).
- Evaluation of treatment tolerability and safety profiles.
Main Results:
- Belimumab demonstrated significant efficacy in patients with autoantibody-positive active SLE on stable background therapy.
- A significantly greater response rate was observed with belimumab compared to placebo in the BLISS trials.
- Belimumab was generally well-tolerated in the studied patient population.
Conclusions:
- Belimumab offers a targeted approach to SLE management by inhibiting BLyS, a key factor in B-cell pathogenesis.
- This biologic therapy shows promise in improving disease control and potentially altering the long-term course of SLE.
- Further research is needed to assess belimumab's long-term safety and efficacy in diverse patient populations.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.